Portal de Periódicos da CAPES

A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan

2000; Wiley; Volume: 18; Issue: 2 Linguagem: Inglês

10.1111/j.1527-3466.2000.tb00038.x

1527-3466

Bernard Waeber,

Renin-Angiotensin System Studies

Cardiovascular Drug ReviewsVolume 18, Issue 2 p. 103-126 Free Access A Review of the Clinical Experience with the Angiotensin II Receptor Antagonist Irbesartan Bernard Waeber MD, Corresponding Author Bernard Waeber MD Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandAddress correspondence and reprint requests to: Bernard Waeber, Professor of Medicine, Division of Pathophysiology, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Tel.: +41 (21) 314-0760. Fax: +41 (21) 314-1432.Search for more papers by this author Bernard Waeber MD, Corresponding Author Bernard Waeber MD Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandAddress correspondence and reprint requests to: Bernard Waeber, Professor of Medicine, Division of Pathophysiology, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Tel.: +41 (21) 314-0760. Fax: +41 (21) 314-1432.Search for more papers by this author First published: 07 June 2006 https://doi.org/10.1111/j.1527-3466.2000.tb00038.xCitations: 5AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Belz GG, Butzer R, Kober S, Mang C, Mutschler E. Time course and extent of angiotensin II antagonism after irbesartan, losartan, and valsartan in humans assessed by angiotensin II dose response and radioligand receptor assay. Clin Pharmacol Ther 1999; 66: 367– 373. 2 Brunner HR. The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 1997; 10: 311S– 317S. 3 Burt VL, Whelton P, Roccella EJ, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension 1995; 25: 305– 313. 4 Caro JJ, Jackson J, Speckman J, Salas M, Raggio G. Compliance as a function of initial choice of antihypertensive drug. Am J Hypertens 1997; 10(part 2): 141A. Abstract. 5 Cazaubon C, Gougat J, Bousquet F, et al. Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 1993; 265: 826– 834. 6 Chando TJ, Everett DW, Kahle AD, et al. Biotransformation of irbesartan in man. Drug Metab Dispos 1998; 26: 408– 17. 7 Christophe B, Libon R, Cazaubon C, Nisato D, Manning A, Chatelain P. Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: Potential mechanisms of action. Eur J Pharmacol 1995; 281: 161– 171. 8 Chung O, Stoll M, Unger T. Physiologic and pharmacologic implications of AT1 versus AT2 receptors. Blood Press 1996; 2(Suppl): 47– 52. 9 Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: Target for drug research J Hypertens 1994; 12(Suppl 2): S1– S5. 10 Fogari R, Ambrosoli S, Corradi L, et al. 24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens 1997; 15: 1511– 1518. 11 Guthrie R, Saini R, Herman T, Pleskow W, Sprecher D, Collins G. Efficacy and tolerability of irbesartan, an angiotensin II receptor antagonist, in primary hypertension. A double-blind, placebo-controlled, dose-titration study. Clin Drug Invest 1998; 15: 217– 227. 12 Havranek EP, Thomas I, Smith WB, et al. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure. J Am Coll Cardiol 1999; 33: 1174– 1181. 13 Hayakawa H, Coffee K, Guerra J, Raij L. Cardio-renal protection by the angiotensin II blocker irbesartan in salt sensitive hypertension. Am J Hypertens 1997; 10: 94A. Abstract. 14 Herbert J-M, Delisée C, Dol F, et al. Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro. Eur J Pharmacol 1994; 251: 143– 150. 15 Howe P, Phillips P, Saini R, Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Clin Exp Hypertens 1999; 22: 1373– 1396. 16 Johnston CI, Naitoh M, Burrell LM. Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues. J Hypertens 1997; 15(Suppl 7): S3– S6. 17 Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413– 2446. 18 Kahan T, Malmqvist K, Edner M, Held C, Osbakken M. Rate and extent of left ventricular hypertrophy regression: A comparison of angiotensin II blockade with irbesartan and beta-blockade. J Am Coll Cardiol 1998; 31(Suppl C): 258C. Abstract. 19 Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension. Am J Hypertens 1998; 11: 445– 53. 20 Kochar M, Guthrie R, Triscari J, Kassler-Taub K., Reeves RA. Matrix study of irbesartan with hydro-chlorothiazide in mild-to-moderate hypertension. Am J Hypertens 1999; 12: 797– 805. 21 Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models. Eur J Pharmacol 1994; 264: 307– 316. 22 Lacour C, Roccon A, Cazaubon C, Segondy D, Nisato D. Pharmacological study of SR 47436, a non-peptide angiotensin II AT1receptor antagonist, in conscious monkeys. J Hypertens 1993; 11: 1187– 1194. 23 Lacour C, Roccon A, Cazaubon C, Segondy D, Nisato D. Hemodynamic and hormonal effects of repeated doses of irbesartan, an angiotensin II antagonist, in monkeys. J Hypertens 1996; 14(Suppl 1): S101. Abstract. 24 Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Am J Cardiol 1997; 80: 1613– 1615. 25 Littlejohn T, Saini R, Kassler-Taub K, Chrysant SG, Marbury T. Long-term safety and antihypertensive efficacy of irbesartan: Pooled results of five open-label studies. Clin Exp Hypertens 1999; 22: 1273– 1295. 26 Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188: 661– 670. 27 Mangold B, Gielsdorf W, Marino MR. Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin. Eur JClin Pharmacol 1999; 55: 593– 598. 28 Marino MR, Hammett JL, Ferreira I, Ford NF, Uderman HD. Effect of nifedipine on the steady-state pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Cardiovasc Pharmacol Ther 1998; 3: 111– 118. 29 Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998; 38: 246– 255. 30 Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of the angiotensin II blocker irbesartan. Clin Drug Invest 1997; 14: 383– 391. 31 Marino MR, Langenbacher KM, Ford NF, et al. Pharmacokinetics and pharmacodynamics of irbesartan in patients with mild to moderate hypertension. J Cardiovasc Pharmacol Ther 1999; 4: 67– 75. 32 Marino MR, Langenbacher KM, Raymond RH, Ford NF, Lasseter KC. Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis. J Clin Pharmacol 1998; 38: 347– 356. 33 Marino MR, Langenbacher KM, Raymond RH, Whigan D, Ford NF. Pharmacokinetics (PK) and antihypertensive effects of irbesartan (an AII receptor antagonist) in subjects with hypertension. J Hypertens 1996; 14: S348. Abstract. 34 Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension 1999; 33: 850– 855. 35 McCombs JS, Nichol MB, Newman CM, Sclar DA. The costs of interrupting antihypertensive drug therapy in a Medicaid population. Med Care 1994; 32: 214– 226. 36 McCune SA, Carraway JW, Radin MJ, Holycross BJ. Comparison of irbesartan to captopril in heart failure prone male SHHF/MCC-FACPrats. J Hypertens 1996; 14(Suppl 1): S137. Abstract. 37 Mimran A, Ruilope L, Kerwin L, et al. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension. J Hum Hypertens 1998; 12: 203– 208. 38 Neutel J, Germino W, Smith D, Park J-S, Reilly K, Triscari J. The antihypertensive efficacy and safety of irbesartan compared with amlodipine for the treatment of mild-to-moderate hypertension. Am J Hypertens 1999; 12(Suppl): 128A. Abstract. 39 O'Donnell MP, Kasiske BL, Keane WF, Powell JR. The angiotensin II receptor antagonist irbesartan reduces blood pressure and glomerular injury in obese Zucker rats. Am J Hypertens 1996; 9(part 2): 80A. Abstract. 40 Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study on the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Clin Ther 1998; 20: 398– 09. 41 Pechère-Bertschi A, Nussberger J, Decosterd L, et al. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients. J Hypertens 1998; 16: 385– 393. 42 Perrier L, Bourrié M, Marti E, et al. In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 1994; 271: 91– 99. 43 Pohl M, Cooper M, Ulrey J, Pauls J, Rohde R. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria. Am J Hypertens 1997; 10: 105A. Abstract. 44 Pool JL, Guthrie RM, Littlejohn TW, III, et al. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension. Am J Hypertens 1998; 11: 462– 470. 45 Pouleur HG. Clinical overview of irbesartan: A new angiotensin II receptor antagonist. Am J Hypertens 1997; 10: 318S– 324S. 46 Powell JR, Reeves RA, Marino MR, Cazaubon C, Nisato D. A review of the new angiotensin II receptor antagonist irbesartan. Cardiovasc Drug Rev 1998; 16: 169– 194. 47 Pylypchuk GB. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema. Ann Pharmacother 1998; 32: 1060– 1066. 48 Raskin P, Guthrie R, Flack J, Reeves R, Saini R. The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide. J Hum Hypertens 1999; 13: 683– 687. 49 Reeves RA, Lin C-S, Kassler-Taub K, Pouleur H. Dose-related efficacy of irbesartan for hypertension: An integrated analysis. Hypertension 1998; 31: 1311– 1316. 50 Ribstein J, Picard A, Armagnac C, Bouroudian M, Sissmann J, Mimran A. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects. J Hypertens 1997; 15(Suppl 4): S117. Abstract. 51 Ribstein J, Sissmann J, Picard A, Bouroudian M, Mimran A. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects. J Hypertens 1994; 12: 131. Abstract. 52 Richer C, Fornes P, Cazaubon C, Domergue V, Nisato D, Giudicelli JF. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. Cardiovasc Res 1999; 41: 100– 108. 53 Roccon A, Marchionni D, Donat F, Segondy D, Cazaubon C, Nisato D. A pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys. Br J Pharmacol 1994; 111: 145– 150. 54 Rodby RA, Rohde RD, Clarke WR, et al. The irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics. Nephrol Dial 2000; 15: 487– 97. 55 Rosenstock J, Rossi L, Lin CS, MacNeil D, Osbakken M. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther 1998; 23: 433– 40. 56 Schmitt F, Martinez F, Brillet G, et al. Acute renal effects of AT1receptor blockade after exogenous angiotensin II infusion in healthy subjects. J Cardiovasc Pharmacol 1998; 31: 314– 321. 57 Sica DA, Marino MR, Hammett JL, Ferreira I, Gehr TWB, Ford NF. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis. Clin Pharmacol Ther 1997; 62: 610– 618. 58 Simon SR, Black HR, Moser M, Berland WE. Cough and ACE inhibitors. Arch Intern Med 1992; 152: 1698– 1700. 59 Simon TA, Gelarden T, Freitag SA, Kassler-Taub KB, Davies R. Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Am J Cardiol 1998; 82: 179– 182. 60 Stockwell DH, Madhavan S, Cohen H, Gibson G, Alderman MH. The determinants of hypertension awareness, treatment, and control in an insured population. Am J Public Health 1994; 84: 1768– 1774. 61 Stumpe KO, Haworth D, Höglund C, et al. Comparison of the angiotensin II receptor antagonist irbesartan with atenolol for treatment of hypertension. Blood Press 1998; 7: 31– 37. 62 Tonkon M, Awan N, Niazi I, et al. A study of the efficacy and safety of irbesartan in combination with conventional therapy, including ace inhibitors, in heart failure. Int J Clin Pract 2000; 54: 11– 18. 63 Urata H, Nishimura H, Ganten D, Arakawa K. Angiotensin-converting enzyme-independent pathways of angiotensin II formation in human tissues and cardiovascular diseases. Blood Press 1996; 5(Suppl 2): 22– 28. 64 Vacher E, Fornes P, Richer C, Bruneval P, Nisato D, Guidicelli J-F. Early and late haemodynamic and morphological effects of angiotensin II subtype 1 receptor blockade during genetic hypertension development. J Hypertens 1995; 13: 675– 682. 65 Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 1998; 38: 702– 707. 66 Vachharajani NN, Shyu WC, Greene DS, Uderman HD. Effects of food on the pharmacokinetics of irbesartan/hydrochlorothiazide combination tablet. Clin Drug Invest 1998; 16: 399– 404. 67 Vachharajani NN, Shyu WC, Mantha S, Park J-S, Greene DS, Barbhaiya RH. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers. J Clin Pharmacol 1998; 38: 433– 36. 68 Vachharajani NN, Shyu WC, Smith RA, Greene DS. The effects of age and gender on the pharmacoki-netics of irbesartan. Br J Clin Pharmacol 1998; 46: 611– 613. 69 Vijay N, Alhaddad IA, Denny DM, et al. Irbesartan compared with lisinopril in patients with mild to moderate heart failure. J Am Coll Cardiol 1998; 31(Suppl A): 188A. Abstract. 70 Ziai F, Ots M, Provoost AP, et al. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure. Kidney Int 1996; 50(Suppl 57): S132– S136. Citing Literature Volume18, Issue2June 2000Pages 103-126 ReferencesRelatedInformation